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Phenotypic
Anchoring: Linking
Cause and Effect
Toxicogenomics combines genetics, tran-
scriptomics (genomic-scale mRNA expres-
sion), proteomics (cell- and tissuewide
protein expression), metabonomics (metabo-
lite profiling), and bioinformatics with
conventional toxicology in an effort to
understand the role of gene–environment
interactions in disease. Central to the
research strategy of the National Center for
Toxicogenomics (NCT) at the NIEHS is
the fundamental concept of “phenotypic
anchoring,” in which studies are designed
to relate specific alterations in gene expres-
sion profiles to specific adverse effects of
environmental stresses defined by conven-
tional parameters of toxicity such as clini-
cal chemistry and histopathology. 
The Toxicology/Pathology (Tox/Path)
Working Group of the NCT performs
experiments designed to gain insight into
mechanisms of toxicity, to establish signa-
tures of effects, and to link the patterns of
altered gene expression to specific parame-
ters of well-defined indices of toxicity.
Such proof-of-principle experiments can
lead to specific applications of genomics,
proteomics, and metabonomics technolo-
gies to toxicology.
The group’s overall approach is guided
by the fact that processes of injury and
repair are highly conserved across many
species. For example, necrosis, apoptosis,
and DNA repair have been studied effective-
ly in nonmammalian and nonprimate sys-
tems because there is such a high degree of
conservation of the various genes involved
in fundamental aspects of these effects.
However, chemicals exert their adverse
effects over dose and time, and there are
modifier genes in various species or strains
that can affect the action of a chemical
through metabolism or during some of the
basic processes of injury and repair. 
Studies are therefore designed to cover
a full range of dose-related effects—from
pharmacologic, to beneficial, to irre-
versibly toxic. The Tox/Path researchers
anticipate that these studies will enable
them to both identify biomarkers of spe-
cific toxicity (by studying well-defined
toxic end points) and apply these biomark-
ers at earlier times and lower doses in a
predictive manner.
Phase One
Studies on transcriptome analysis make up
the first phase of Tox/Path efforts. The
group hopes these studies will lead to the
identification of a minimum set of genes
that may be candidate biomarkers for spe-
cific toxic effects. At the same time, tissue
and serum are being collected from the
proof-of-principle experiments for simulta-
neous proteomic analysis. The results of the
transcriptome studies can serve as a guide in
the search for specific proteins that could be
used as biomarkers of incipient toxicity. 
The ultimate linkage of candidate bio-
markers to the actual causal processes that
lead to specific toxic effects will be accom-
plished through studies involving in situ
hybridization, immunohistochemistry, and
the laser-capture microdissection of cells to
relate the expression of the putative bio-
markers to the specific cells that have
undergone these adverse events. 
Studies from the NCT have demon-
strated the capability of identifying signa-
ture patterns of altered gene expression that
can be used to predict the classes of chemi-
cals that an animal was exposed to based on
an initial training set of chemicals. Joint
research by scientists at the NIEHS Micro-
array Center and Boehringer Ingelheim
Pharmaceuticals performed on acutely
exposed animals has shown that global gene
expression profiles for chemicals from dif-
ferent mode-of-action classes can provide
gene expression signatures of chemical
exposures in male rats.
This work led to the hypothesis that it
would be possible to define signature pat-
terns of altered gene expression that indi-
cate specific adverse effects of chemical,
drug, or environmental exposures. The
idea is that once signatures are identified
using large-scale global microarray analy-
sis, it will then be possible to develop
smaller multichemical and multipathway
arrays that can be used to assess the
potential toxicity of chemicals in a rapid,
prospective manner. 
This phenotypic anchoring of gene
expression data to toxicological and patho-
logical indices removes some of the subjec-
tivity of conventional molecular expression
analyses. It also helps to distinguish the
toxicological effect signal from other gene
expression changes that may be unrelated
to toxicity, such as the varied pharmaco-
logical or therapeutic effects of a com-
pound. This distinction could mean better
interspecies extrapolation, greater confi-
dence in animal models, reduction in the
number of animals needed for testing, faster
testing, and, most important, insights into
pathways of toxicity and disease processes
and their mechanisms that have been
heretofore unattainable. 
Fine-tuning the Approach
In testing this hypothesis, the Tox/Path
Working Group is taking a three-part
strategic approach. The first component of
the strategy is to select agents that induce
specific types of toxicity in both rodent
models and humans. The initial focus is on
hepatotoxic substances. For example,
experiments are being designed to correlate
gene expression patterns with liver patholo-
gies such as hepatocellular necrosis and
inflammation. The group will also look for
correlative patterns, for example with other
classic parameters of hepatic toxicity such
as changes in serum enzyme levels. 
The second component of the strategy
is to select several structurally and func-
tionally diverse chemicals and drugs that
also are hepatotoxic, in order to generate
comparative data (no two chemicals pro-
duce exactly the same pattern of hepato-
toxicity). The process of injury is itself
extremely complex, from the initial point
of exposure through metabolism, damage,
repair, and cell death. The Tox/Path
researchers believe that by selecting a num-
ber of agents and carefully defining the
toxic effects of those agents through the
application of bioinformatics tools, they
can identify specific groups of genes whose
expression is altered and causally related to
the specific toxicity. 
The third component of the strategy is
to use nontoxic isomers of hepatotoxi-
cants to analyze effects in target and non-
target tissues, for example by comparing
the effects of hepatotoxic chemicals in
both the liver and the kidney. Gene
expression changes in the liver will also be
compared with expression changes in sur-
rogate tissues such as blood in a so-called
matrix approach. 
Opening Doors
The philosophy of the Tox/Path Working
Group is that only through a strategic,
incremental study of specific agents and
specific toxic effects can the most appropri-
ate ways in which to use toxicogenomics
technology in toxicology be identified. The
group anticipates this will be a long-term
process requiring a learning set of a sub-
stantial number of chemicals and drugs in
order to achieve a meaningful array of can-
didate biomarkers. If such biomarkers can
be established for processes such as hepato-
toxicity, the approach may provide a strong
stimulus for the search for biomarkers for
other tissue- and organ-specific toxicities
such as vasculitis, cardiotoxicity, and can-
cer, for which surrogate models provide
poor predictive power. 
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the application of global transcription
analysis provides the opportunity for true
discovery of novel entities such as poten-
tial biomarkers that cannot be hypothe-
sized on the basis of the current state of
knowledge. Such opportunities may revo-
lutionize science’s ability to characterize
hazard. However, the challenge in the near
future is to establish a body of available
knowledge to serve as a
foundation for apply-
ing the data generated
by these new methods
to risk assessment. 
The scope of toxi-
cology experimentation
performed with toxi-
cogenomics technologies
is still relatively limited.
Few data are publicly
available, and broad
consensus on the appli-
cation and interpretation
of them has not been
reached in international
regulatory and scientific
arenas. There is signifi-
cant need for a coordi-
nated evaluation effort
and a publicly available
knowledge base.
Work in genomics
will also result in a
greater understanding of
the mechanisms of
chemical toxicity. This
understanding will come
through the determina-
tion of relationships
between chemical expo-
sure and changes in
genomewide gene and
protein expression pat-
terns, or changes in pat-
terns of metabolites. An
understanding of the
consequences of pattern
changes is critically
important in developing
a complete understand-
ing of toxicological
processes, because gene
expression is altered either directly or indi-
rectly as a result of toxicant exposure in
almost all cases examined. The spectrum of
the altered genes or proteins then determines
the type and outcome of the toxic response. 
Viewed in this manner, patterns of
gene and protein expression, or alterations
in endogenous metabolism, can be used as
markers of exposure and as methods for
identifying mechanisms of toxicity. The
simultaneous analysis of thousands of
end points will allow toxicologists to take
a new look at toxicological issues that
cannot be completely understood using
nongenomics techniques including mode
of action, dose–response relationships,
chemical interactions and hazard identifi-
cation in chemical mixtures, and human
exposure assessment.
The Tox/Path researchers hope that the
combined and integrated data on gene, pro-
tein, and metabolite changes collected in
the context of dose, time, target tissue, and
phenotypic severity across species will pro-
vide the interpretive information needed to
define the molecular basis for chemical toxi-
city and to model the resulting toxicological
and pathological outcomes.
Future NCT studies will explore quanti-
tative or absolute gene expression profiling
and consider combining such an approach
with physiologically based pharmacokinetic
and pharmacodynamic modeling. Phar-
macokinetic modeling can be used to derive
a quantitative estimate of target tissue dose
at any time after treatment, thus creating the
possibility to anchor molecular expression
profiles in internal dose, as well as in time
and phenotypic severity.
Relationships among
gene, protein, and me-
tabolite expression may
then be described as a
function of the applied
dose of an agent and
the ensuing kinetic and
dynamic dose–response
behavior in various tis-
sue compartments. Sci-
entists would then be
able to search for evi-
dence of exposure or
injury prior to any
clinical or pathological
manifestation, facili-
tating identification of
early biomarkers of
exposure, toxic injury,
and susceptibility. 
Toxicogenomics
research will likely lead
to the identification,
measurement, and eval-
uation of biomarkers
that are more accurate,
quantitative, and spe-
cific. These biomarkers
will be recognized as
important factors in a
sequence of key events
that will help to define
the way in which spe-
cific chemicals and
environmental expo-
sures cause disease. 
Researchers in the
Tox/Path Working
Group anticipate that
understanding of the
mechanisms of toxicity
and disease will im-
prove as new toxicogenomics methods are
used more extensively and as toxicoge-
nomics databases are developed more
fully. The end result will be the emer-
gence of toxicology as an information sci-
ence that will enable thorough analysis,
iterative modeling, and discovery across
biological species and chemical classes.
–Richard Paules
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